Literature DB >> 33871695

Transforming growth factor β as a possible independent factor in chronic hepatitis B.

Ming-Hui Li1,2, Yao Lu1, Fang-Fang Sun1, Qi-Qi Chen2, Lu Zhang1, Hui-Hui Lu1, Zhan Zeng2, Wei Yi3, Yao Xie4,5.   

Abstract

To investigate the association between immune-cell-related cytokines and the development of chronic hepatitis B (CHB), patients with chronic hepatitis B virus (HBV) infection in the immunotolerant (IT) phase (n = 30) or hepatitis B envelope antigen (HBeAg)-positive CHB (n = 250) were enrolled in this study. Serological indicators and plasma cytokine levels were measured at the time of enrollment. The results showed that there were significant differences in the median age of the patients (27 vs. 31 years), alanine aminotransferase levels (ALT, 29.85 vs. 234.70 U/L), alanine aminotransferase levels (AST, 23.40 vs. 114.90 U/L), HBsAg levels (4.79 vs. 3.88 log10 IU/ml), HBeAg levels (1606.36 vs. 862.47 S/CO), and the HBV DNA load (8.17 vs. 6.71 log10 IU/ml) between the IT and CHB groups (all P < 0.01). The median values of Fms-like tyrosine kinase 3 ligand (FLT3-L), interferon-gamma (IFN-γ), interleukin- 17A (IL-17A), and transforming growth factor beta (TGF-β1) were significantly higher in the IT group than in the CHB group (FLT3-L, 41.62 vs. 27.47 pg/ml; IFN-γ, 42.48 vs. 33.18 pg/ml; IL-17A, 15.66 vs. 8.90 pg/ml; TGF-β1, 4921.50 vs. 2234 pg/ml; all P < 0.01). The median IFN-α2, TGF-β3 and IL-10 levels in the IT group were significantly lower than those in the CHB group (IFN-α2, 15.24 vs. 35.78 pg/ml, P = 0.000; TGF-β3, 131.69 vs. 162.61 pg/ml, P = 0.025; IL-10, 5.02 vs. 7.9 pg/ml, P = 0.012). Multivariate logistic regression analysis indicated that TGF-β 1 (OR = 0.999, 95% CI 0.999-1.000, P < 0.001) and TGF-β2 levels (OR = 1.008, 95%CI 1.004-1.012, P < 0.001) were modestly but significantly associated with the incidence of CHB. The results suggest that TGF-β level might be an independent factor related to the occurrence of CHB.

Entities:  

Year:  2021        PMID: 33871695     DOI: 10.1007/s00705-021-05062-6

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  2 in total

1.  Clinical outcomes for COVID-19 patients with diabetes mellitus treated with convalescent plasma transfusion in Wuhan, China.

Authors:  Wei Dai; Jian Wu; Tianfu Li; Jiawei Shen; Rongrong Pang; Tao Luo; Yanju Guo; Yang Yang; Jun Zhao; Mingchao Zhang; Na Li; Ying Han; Qiuyue Wu; Weiwei Li; Xinyi Xia
Journal:  J Med Virol       Date:  2020-12-17       Impact factor: 2.327

2.  Defective natural killer cell anti-viral capacity in paediatric HBV infection.

Authors:  I L Heiberg; L J Pallett; T N Winther; B Høgh; M K Maini; D Peppa
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

  2 in total
  2 in total

1.  Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients.

Authors:  Minghui Li; Fangfang Sun; Xiaoyue Bi; Yanjie Lin; Liu Yang; Yao Lu; Lu Zhang; Gang Wan; Wei Yi; Linqing Zhao; Yao Xie
Journal:  Virol Sin       Date:  2022-03-04       Impact factor: 6.947

2.  Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B.

Authors:  Minghui Li; Yuanjiao Gao; Liu Yang; Yanjie Lin; Wen Deng; Tingting Jiang; Xiaoyue Bi; Yao Lu; Lu Zhang; Ge Shen; Ruyu Liu; Shuling Wu; Min Chang; Mengjiao Xu; Leiping Hu; Rui Song; Yuyong Jiang; Wei Yi; Yao Xie
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.